Ponesimod

Phase 3

Vanda Pharmaceuticals Inc. (VNDA)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Moderate-to-severe Chronic Plaque Psoriasis

View Full Landscape

Drug Information

Target Indication

Moderate-to-severe Chronic Plaque Psoriasis

Clinical Trial

NCT07362017

Last updated: 6/11/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA5/19/2021

Ponvory

Ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

VNDA

Vanda Pharmaceuticals Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

TradipitantPhase 3

Motion Sickness

20 mg VEC-162Phase 3

Insomnia

VEC-162 20 mgPhase 3

Primary Insomnia

Tasimelteon Oral SuspensionPhase 3

Insomnia Disorder

Tasimelteon Oral Capsule, Tasimelteon Liquid SuspensionPhase 3

Autism Spectrum Disorder

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts